13F Holdings
中文EN

NBP NovaBridge Biosciences

Pharmaceutical Preparations · Nasdaq · SEC CIK 1778016 · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY140.7%
TTM net income YoY44.0%
TTM EPS YoY44.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-11,395.1%
Net margin-32,868.5%
FCF margin-11,528.6%
EBITDA margin-11,319.9%

Returns

ROE-62.9%
ROA-43.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets34.2%
Debt / equity0.00x
Current ratio5.67x
Interest coverage-706.05x

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-28.1%
Payout ratio—
Capex / revenue25.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$632,000-$1.55M$13.81M
Cost of revenue———$3.95M$7.29M
Gross profit———-$5.50M$6.53M
R&D expense$62.91M$21.77M$21.45M$22.55M$190.34M
SG&A expense$31.36M$29.66M$28.16M$28.98M$141.22M
Operating income-$94.27M-$51.43M-$72.02M-$53.08M—
Interest expense——$102,000$1,000$0
Pretax income-$88.34M-$49.70M-$82.22M-$141.10M-$366.37M
Income tax$0$0$0$103,000-$495,000
Net income-$46.27M-$22.23M-$207.73M-$371.05M-$365.87M
EBITDA-$94.20M-$51.16M-$71.54M-$52.88M—
EPS (basic)-0.21-0.12-1.09-1.96-2.09
EPS (diluted)-0.21-0.12-1.09-1.96-2.09
Weighted avg. shares (diluted)220.26M186.73M191.42M189.79M174.71M
Balance sheet
Cash & equivalents$210.63M$68.26M$291.51M$475.37M$552.67M
Short-term investments$210,000$105.14M$20.22M$34.13M$118.19M
Receivables———$0$5.19M
Inventory———$0$4.27M
Current assets$217.52M$176.69M$329.91M$525.79M$750.36M
PP&E, net$140,000$201,000$1.78M$8.82M$7.17M
Goodwill———$23.57M$25.51M
Intangibles——$16.64M$17.24M$18.78M
Total assets$260.52M$212.68M$368.92M$590.62M$878.95M
Current liabilities$26.89M$8.45M$58.14M$109.92M$97.92M
Short-term debt——$4.22M$2.75M—
Total liabilities$29.58M$11.52M$126.34M$168.73M$163.45M
Shareholders' equity$230.94M$201.16M$242.58M$417.81M$715.15M
Shares outstanding265.38M187.45M185.61M190.88M183.83M
Cash flow statement
Operating cash flow-$20.60M-$52.67M-$72.70M-$49.58M-$152.70M
Capital expenditure$7,000$48,000$164,000$2.09M$4.70M
Free cash flow-$20.60M-$52.72M-$72.86M-$51.67M-$157.40M
Investing cash flow$104.97M-$136.01M-$15.16M-$5.18M-$114.11M
Financing cash flow$57.73M-$335,000-$8.24M$3.91M$93.20M
Depreciation & amortization$68,000$261,000$475,000$200,000$2.16M
Stock-based compensation$5.97M-$1.95M$10.24M$13.15M$95.50M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.